Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

The New England journal of medicine - 17 May 2018

Gounder Mrinal M, Solit David B, Tap William D

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histiocytic Disorders and Treatments
Share to MAP Kinase Kinase 1
Share to Metabolic Networks and Pathways
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 29768143
DOI: 10.1056/NEJMc1511490
PMCID: PMC6062005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.PMID 29768143Read ↗

Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.Semantic proximity Read ↗

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.Semantic proximity Read ↗

Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic OverviewSemantic proximity Read ↗

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.Semantic proximity Read ↗

Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 DeletionSemantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanibSemantic proximity Read ↗

Effective treatment with Dabrafenib and Trametinib for a BRAF-mutated metastatic dedifferentiated malignant spindle cell neoplasm.Semantic proximity Read ↗

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.Semantic proximity Read ↗

Efficacy of MEK inhibition in patients with histiocytic neoplasmsSemantic proximity Read ↗

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.